Therapeutic Potential of Topical Cannabis for the Treatment of Psoriasis:  A Preliminary Clinical Evaluation of Two Different Formulations

Thanvisith Charoenying; Kamolrak Lomwong; Pichit Boonkrong; Wantika Kruanamkam

doi:10.59796/jcst.V14N1.2024.6

Authors

Thanvisith Charoenying Faculty of Allied Health Sciences, Pathumthani University, Pathum Thani 12000, Thailand
Kamolrak Lomwong Biomedical Sciences Graduate Program, Department of Medical Science, Faculty of Science, Rangsit University, Pathum Thani 12000, Thailand
Pichit Boonkrong College of Biomedical Engineering, Rangsit University, Pathum Thani 12000, Thailand
Wantika Kruanamkam Department of Biomedical Sciences, Faculty of Science, Rangsit University, Pathum Thani 12000, Thailand

DOI:

https://doi.org/10.59796/jcst.V14N1.2024.6

Keywords:

cannabis, medicinal plants, psoriasis, therapeutic potential, THC, CBD

Abstract

The aim of this study is to investigate the potential therapeutic benefits of using cannabis-enriched topical cream containing of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), either alone (THC:CBD) or in combination with a polyherbal formulation for treating psoriasis. To evaluate the efficacy and safety of both formulations, a crossover, randomized, single-blinded study was conducted on 20 volunteers who were monitored for key indicators such as PASI score, PDI, DLQI, and blood profile. The present study involved two eight-week treatment periods with each formulation, separated by a two-week washout period. The results showed that the group using the cannabis cream comprising of THC:CBD alone experienced a significant reduction in PASI score after four weeks over the course of the 8-week study. Furthermore, the combination of THC:CBD and the polyherbal formulation was found to be more effective in reducing disease severity and improving patient quality of life. No significant adverse reactions were observed, and there was no difference in blood profile before and after treatment. These findings indicate that both topical formulations are safe and effective for treating psoriasis, with the combined formulation showing greater potential than using topical cannabis alone.

References

Assanangkornchai, S., Thaikla, K., Talek, M., & Saingam, D. (2022). Medical cannabis use in Thailand after its legalization: A respondent-driven sample survey. PeerJ, 10, Article e12809. https://doi.org/10.7717/PEERJ.12809/SUPP-3

Atakan, Z. (2012). Cannabis, a complex plant: different compounds and different effects on individuals. Therapeutic Advances in Psychopharmacology, 2(6), 241-254. https://doi.org/10.1177/2045125312457586

Bíró, T., Tóth, B. I., Haskó, G., Paus, R., & Pacher, P. (2009). The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends in pharmacological sciences, 30(8), 411-420. https://doi.org/10.1016/J.TIPS.2009.05.004

Boonyaroon, N., & Sirisutisuwon, N. (2020). Clinical trial: The effects of “Thai-bio®” skin care cream to relieve symptoms and improve quality of life in patients suffering from Psoriasis. [Unpublished Bachelor’s Thesis], Rangsit University.

Christophers, E. (2001). Psoriasis--epidemiology and clinical spectrum. Clinical and experimental dermatology, 26(4), 314–320. https://doi.org/10.1046/J.1365-2230.2001.00832.X

Costa, B., Giagnoni, G., Franke, C., Trovato, A. E., & Colleoni, M. (2004). Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. British journal of pharmacology, 143(2), 247–250. https://doi.org/10.1038/SJ.BJP.0705920

Department of Thai Traditional and Alternative Medicine. (2022, April). Medical Cannabis. Wellness Magazine. Retrieved from https://thaicam.go.th/wp-content/uploads/2022/01/wellness-Jan-2022-1.pdf

Fisher, E., Moore, R. A., Fogarty, A. E., Finn, D. P., Finnerup, N. B., Gilron, I., ... & Eccleston, C. (2021) (2021). Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain, 162, S45–S66. https://doi.org/10.1097/j.pain.0000000000001929

Fraguas-Sánchez, A. I., Fernández-Carballido, A., Martin-Sabroso, C., & Torres-Suárez, A. I. (2020). Stability characteristics of cannabidiol for the design of pharmacological, biochemical and pharmaceutical studies. Journal of Chromatography B, 1150, Article 122188. https://doi.org/10.1016/J.JCHROMB.2020.122188

Hashiesh, H. M., Sharma, C., Goyal, S. N., Jha, N. K., & Ojha, S. (2021). Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist. Frontiers in Pharmacology, 12, Article 702675. https://doi.org/10.3389/FPHAR.2021.702675/BIBTEX

Hess, C., Krämer, M., & Madea, B. (2017). Topical application of THC containing products is not able to cause positive cannabinoid finding in blood or urine. Forensic science international, 272, 68–71. https://doi.org/10.1016/J.FORSCIINT.2017.01.008

Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., ... & Pertwee, R. G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological reviews, 54(2), 161–202. https://doi.org/10.1124/PR.54.2.161

Institute for Quality and Efficiency in Health Care (IQWiG). (2017). Psoriasis: Oral medications and injections - InformedHealth.org -. Retrieved Januscry, 22, 2023 from https://www.ncbi.nlm.nih.gov/books/NBK435704/

Jaipakdee, N., Tabboon, P., Limpongsa, E. (2022). Application of a liquisolid technique to cannabis sativa extract compacts: Effect of liquid vehicles on the dissolution enhancement and stability of cannabinoids. International Journal of Pharmaceutics, 612, Article 121277

Kohda, H., Hino, H., Yuwao, F., & Urabe, H. (1995). Adverse effects of topical corticosteroid use. Western Journal of Medicine, 162(2), 123-126. https://doi.org/10.2336/nishinihonhifu.40.177

Martins, A. M., Gomes, A. L., Boas, I. V., Marto, J., & Ribeiro, H. M. (2022). Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review. Pharmaceuticals, 15(2), Article 210. https://doi.org/10.3390/PH15020210

Ministry of Public Health. (n.d.). DTAM GANJA OIL (DEJA FORMULA). Opgehaal 13 Mei 2023, van https://www.medcannabis.go.th/blog/น้ำมันกัญชา (ตำรับหมอเดชา)

Moore, R. A., Fisher, E., Finn, D. P., Finnerup, N. B., Gilron, I., Haroutounian, S., ... & Eccleston, C. (2021). Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews. Pain, 162(Suppl 1), S67–S79. https://doi.org/10.1097/J.PAIN.0000000000001941

Morales, P., & Reggio, P. H. (2017). An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors. Cannabis and Cannabinoid Research, 2(1), 265. https://doi.org/10.1089/CAN.2017.0036

Madaka, F., Chankana, N., Khamthong, N., Maha, A., Songsak, T. (2021). Extraction and isolation of high quantities of Cannabidiol, Cannabinol, and Delta-9-tetrahydrocannabinol from Cannabis sativa L. Malaysian Journal of Analytical Sciences, 25(5), 867 - 881

Nestle, F. O., Kaplan, D. H., & Barker, J. (2009). Psoriasis. New England Journal of Medicine, 361(5), 496–509. https://doi.org/10.1056/NEJMra0804595

Norooznezhad, A. H., & Norooznezhad, F. (2017). Cannabinoids: Possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation. Medical hypotheses, 99, 15–18. https://doi.org/10.1016/J.MEHY.2016.12.003

Osiripun, V., & Labua, S. (2023). Effects of thermal processing on cannabidiol degradation in cannabidiol-infused pomegranate juice and evaluation of its antioxidant property. Journal of Current Science and Technology, 13(1), 107–117. https://doi.org/10.14456/jcst.2023.10

Palmieri, B., Laurino, C., & Vadala, M. (2019). A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars. La Clinica terapeutica, 170(2), E93–E99. https://doi.org/10.7417/CT.2019.2116

Pathompak, P., Chankana, N., Vipunngeun, N., & Phonkratho, S. (2022). HPLC method development and validation for quantitation of CBD and THC in Suk-SaiYas Pills | Journal of Current Science and Technology. Journal of Current Science and Technology, 12(3), 538–546. https://doi.org/10.14456/jcst.2022.41

Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., … & Ross, R. A. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂. Pharmacological reviews, 62(4), 588–631. https://doi.org/10.1124/PR.110.003004

Ramot, Y., Sugawara, K., Zákány, N., Tóth, B. I., Bíró, T., & Paus, R. (2013). A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ. PeerJ, 1(1), Article e40. https://doi.org/10.7717/PEERJ.40

Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochemical research, 30(8), 1037–1043. https://doi.org/10.1007/S11064-005-6978-1

Schräder, N. H.B., Duipmans, J. C., Molenbuur, B., Wolff, A. P., & Jonkman, M. F. (2019). Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases. British Journal of Dermatology, 180(4), 922–924. https://doi.org/10.1111/BJD.17341

Schräder, N. H., Gorell, E. S., Stewart, R. E., Duipmans, J. C., Harris, N., Perez, V. A., ... & Bolling, M. C. (2021). Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study. Orphanet Journal of Rare Diseases, 16(1), 377. https://doi.org/10.1186/S13023-021-02010-0

Shao, K., Stewart, C., & Grant-Kels, J. M. (2021). Cannabis and the skin. Clinics in Dermatology, 39(5), 784–795. https://doi.org/10.1016/J.CLINDERMATOL.2021.05.006

Sheriff, T., Lin, M. J., Dubin, D., & Khorasani, H. (2020). The potential role of cannabinoids in dermatology. Journal of Dermatological Treatment, 31(8), 839–845. https://doi.org/10.1080/09546634.2019.1675854

Silarak, K. (2022). Efficacy of Cannabis Oil (Deja’s Formula) on Out-Patients’ Sleep Quality and Quality of Life at Hang Ga Rok Clinic : Phra Arjarn Phan Arjaro Hospital, Sakhon Nakhon Province. Regional Health Promotion Center 9 Journal, 16(3), 1097–1108.

Ständer, S., Schmelz, M., Metze, D., Luger, T., & Rukwied, R. (2005). Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. Journal of dermatological science, 38(3), 177–188. https://doi.org/10.1016/J.JDERMSCI.2005.01.007

Takeda, K., Arase, S., & Takahashi, S. (1988). Side Effects of Topical Corticosteroids and their Prevention. Drugs, 36(5), 15–23. https://doi.org/10.2165/00003495-198800365-00005/METRICS

Thatiparthi, A., Martin, A., Liu, J., & Wu, J. J. (2022). Risk of Skin Cancer with Phototherapy in Moderate-to-Severe Psoriasis: An Updated Systematic Review. The Journal of Clinical and Aesthetic Dermatology, 15(6), 68-75.

The Government Pharmaceutical Organization (GPO) Thailand. (2019, November 20). Guidelines for the use of medicinal-grade cannabis extracts in dermatological conditions. https://www.gpo.or.th/view/54

Wallace, M. J., Wiley, J. L., Martin, B. R., & DeLorenzo, R. J. (2001). Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. European journal of pharmacology, 428(1), 51–57. https://doi.org/10.1016/S0014-2999(01)01243-2

Wilkinson, J. D., & Williamson, E. M. (2007). Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. Journal of Dermatological Science, 45(2), 87–92. https://doi.org/10.1016/J.JDERMSCI.2006.10.009

Wroński, A., Jarocka-Karpowicz, I., Stasiewicz, A., & Skrzydlewska, E. (2023). Phytocannabinoids in the Pharmacotherapy of Psoriasis. Molecules, 28(3), 1192. https://doi.org/10.3390/MOLECULES28031192/S1

Xu, H., Cheng, C. L., Chen, M., Manivannan, A., Cabay, L., Pertwee, R. G., ... & Forrester, J. V. (2007). Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. Journal of leukocyte biology, 82(3), 532–541. https://doi.org/10.1189/JLB.0307159

Yuan, C., Wang, X. M., Guichard, A., Tan, Y. M., Qian, C. Y., Yang, L. J., & Humbert, P. (2014). N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: results of a randomized, double-blind, controlled study in 60 patients. Clinical Interventions in Aging, 9, 1163-1169. https://doi.org/10.2147/CIA.S65448